Ramucirumab Plus Erlotinib Demonstrates Superior Progression-Free Survival in Untreated EGFR+ NSCLC

Strategic Insights -

Research published in Clinical Lung Cancer suggests that the combination of ramucirumab plus erlotinib (RAM + ERL) exhibits benefit compared with placebo plus erlotinib (PBO + ERL) in patients with untreated, metastatic, EGFR-mutated non-small-cell lung cancer (EGFR+ NSCLC). This study, known as RELAY, investigated the relationship between TP53 status and clinical outcomes in patients treated with RAM + ERL. The findings indicate that mutant TP53 is a negative prognostic factor in patients with EGFR + NSCLC, but the addition of a VEGF inhibitor improves outcomes in those with mutant TP53.

Key Takeaways:

  • The RELAY regimen is an efficacious first-line treatment option for all patients with EGFR + NSCLC, with or without TP53 mutation.
  • Ramucirumab plus erlotinib (RAM + ERL) demonstrated superior progression-free survival (PFS) compared with placebo plus erlotinib (PBO + ERL) in the RELAY trial.
  • Mutated TP53 was detected in 165 (42.7%) patients, while wild-type TP53 was detected in 221 (57.3%) patients.
  • Patient and disease characteristics and concurrent gene alterations were comparable between those with mutant and wild-type TP53.
  • Independent of treatment, TP53 mutations were associated with worse clinical outcomes.
  • The addition of a VEGF inhibitor improved outcomes in patients with mutant TP53.
  • The safety profiles were comparable between those with baseline TP53 mutation and wild-type.
  • This analysis indicates that while TP53 mutations are a negative prognostic marker in EGFR+ NSCLC, the addition of a VEGF inhibitor improves outcomes.
  • RAM + ERL is an efficacious first-line treatment option for patients with EGFR+ NSCLC, independent of TP53 status.
  • The study included 386 patients with untreated, metastatic, EGFR-mutated NSCLC who received RAM + ERL or PBO + ERL.

Statistics:

  • 42.7% of patients had mutant TP53, while 57.3% had wild-type TP53.
  • RAM + ERL improved PFS by 39% compared with PBO + ERL in the RELAY trial.
  • ORR and DCR were comparable across all patients, while DoR was superior with RAM + ERL.
  • 221 patients had wild-type TP53, while 165 patients had mutant TP53.
  • The RELAY regimen is an efficacious first-line treatment option for all patients with EGFR + NSCLC, with or without TP53 mutation.

Sources:

  • Relay, Ramucirumab Plus Erlotinib (Ram Plus Erl) In Untreated Metastatic Egfr-mutant Nsclc (Egfr Plus Nsclc) : Association Between Tp53 Status and Clinical Outcome. Clinical Lung Cancer, 2023;24(5):415-428.
  • NewsRx. Studies from Cancer Institute Hospital Have Provided New Information about Monoclonal Antibodies [Relay, Ramucirumab Plus Erlotinib (Ram Plus Erl) In Untreated Metastatic Egfr-mutant Nsclc (Egfr Plus Nsclc) : Association Between Tp53 Status and ...]. Immunotherapy Weekly. August 23, 2023; p 1586.